A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group and Phase III Clinical Trial to Evaluate in Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Cilostazol/ginkgo biloba (Primary)
- Indications Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- Sponsors SK Chemicals
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.
- 11 Oct 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 11 Oct 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.